BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Week In Review | Sep 19, 2016
Company News

Catalyst Biosciences hematology news

Catalyst will reduce headcount by 10 (50%) to about 10 to focus resources on its hemostasis programs, primarily CB 813d and CB 2679d ( ISU 304 ). The company said it will continue to explore licensing...
BC Week In Review | Jun 29, 2015
Clinical News

PF-05280602: Phase I data

An open-label, international Phase I trial in 25 male hemophilia A or B patients with or without inhibitors showed that single doses of 4.5-30 ug/kg IV PF-05280602 were well tolerated and led to no antibody...
BC Week In Review | May 11, 2015
Company News

Catalyst Biosciences, Wyeth deal

Pfizer Inc. (NYSE:PFE, New York, N.Y.) will exercise its right to terminate a 2009 deal granting Wyeth, now part of Pfizer, an exclusive, worldwide license to develop and commercialize the biotech’s PF-05280602 for bleeding in...
BioCentury | Mar 2, 2015
Product Development

The roots of rarity

Pfizer Inc. is expanding its rare disease development toolkit to include technologies that act upstream of protein expression to treat the root cause of disease, with an emphasis on adeno-associated viral vectors to correct loss-of-function...
BC Week In Review | Jan 16, 2012
Clinical News

PF-05280602: Phase I started

Catalyst said Pfizer began an open-label Phase I trial to evaluate single doses of 0.5, 1.5, 4.5, 9, 18 and 30 µg/kg IV PF-05280602 in about 36 adults with hemophilia A and B. The trial...
BC Week In Review | Jul 6, 2009
Company News

Catalyst Biosciences, Wyeth deal

Catalyst granted Wyeth exclusive, worldwide rights to develop and commercialize its CB 813 , a recombinant human coagulation Factor VIIa (rhFVIIa) in preclinical development to treat and prevent acute bleeding in hemophilia patients. Catalyst and Wyeth...
BC Extra | Jul 1, 2009
Company News

Catalyst, Wyeth in Factor VIIa deal

Catalyst BioSciences Inc. (South San Francisco, Calif.) granted Wyeth (NYSE:WYE) exclusive, worldwide rights to develop and commercialize CB 813 , a recombinant human coagulation Factor VIIa that is in preclinical development to treat and prevent acute...
BC Extra | Dec 4, 2008
Top Story

Catalyst raises $40.4 million

Catalyst Biosciences (South San Francisco, Calif.) raised $40.4 million in a series C round led by new investor Essex Woodlands Health Ventures. Existing investors Burrill; HealthCare Ventures; Johnson & Johnson Development Corp.; Morgenthaler Ventures; Novartis...
BioCentury | Jan 14, 2008
Strategy

Specifying proteases

Since its inception in 2003, Catalyst Biosciences Inc. has focused on developing proteases as drugs rather than as targets. In the intervening years, it has acquired the technology needed to reduce the concept to practice,...
Items per page:
1 - 10 of 10